Loading...
Loading...
AUPH| Name | Value |
|---|---|
| Revenues | 54.5M |
| Cost of Revenue | 6.8M |
| Gross Profit | 47.7M |
| Operating Expense | 64.0M |
| Operating I/L | -16.3M |
| Other Income/Expense | 3.1M |
| Interest Income | 4.5M |
| Pretax | -13.1M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -13.4M |
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that focuses on developing and commercializing therapies to address unmet medical needs. The company's flagship product, LUPKYNIS, is targeted at treating adult patients with active lupus nephritis. Through a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., Aurinia Pharmaceuticals generates revenue from the sales of LUPKYNIS. The company's primary business revolves around the development, commercialization, and marketing of innovative therapies for various diseases, particularly focusing on lupus nephritis treatment.
